For Consumers
-
Viral Hepatitis Therapies
Click on drug brand name for additional information.
Approved Treatments for Hepatitis B
| Brand Name | Generic Names | Manufacturer Name | Indication |
|---|---|---|---|
| Baraclude | entecavir | Bristol-Myers Squibb | chronic hepatitis B virus infection with evidence of active viral replication |
| Epivir-HBV | lamivudine | GlaxoSmithKline | chronic hepatitis B associated with hepatitis B viral replication and active liver inflammation |
| Hepsera | adefovir dipivoxil | Gilead Sciences | chronic hepatitis B in patients ≥12 years of age |
| Intron A | interferon alpha-2b | Schering | chronic hepatitis B in patients 1 year of age or older with compensated liver disease |
| Pegasys | pegylated interferon | Roche | treatment of adult patients with HBeAg positive and HBeAg negative chronic hepatitis B who have compensated liver disease and evidence of viral replication and liver inflammation |
| Tyzeka | telbivudine | Novartis | chronic hepatitis B in adult patients with evidence of viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease |
| Viread | tenofovir | Gilead Sciences | chronic hepatitis B in adults. |
Approved Treatments for Hepatitis C
| Brand Name | Generic Names | Manufacturer Name | Indication |
|---|---|---|---|
| Incivek | telaprevir | Vertex Pharmaceuticals | in combination with peginterferon alfa and ribavirin, for the treatment of genotype 1 chronic hepatitis C (CHC) in adult patients with compensated liver disease, including cirrhosis, who are treatment-naïve or who have been previously treated with interferon-based treatment, including prior null responders, partial responders, and relapsers |
| Victrelis | boceprevir | Merck & Co. | treatment of chronic hepatitis C (CHC) genotype 1 infection, in combination with peginterferon alfa and ribavirin, in adult patients (≥18 years of age) with compensated liver disease, including cirrhosis, who are previously untreated or who have failed previous interferon and ribavirin therapy. |
| Pegasys | pegylated interferon | Roche | treatment of adults with chronic hepatitis C virus infection who have compensated liver disease and have not been previously treated with interferon alpha |
| CoPegus | ribavirin | Roche | use in combination with Pegasys or with Roferon for the treatment of adults with chronic hepatitis C virus infection who have compensated liver disease and have not been previously treated with interferon alpha |
| Pegintron | pegylated interferon alpha-2b | Schering | in combination with rebetol, is indicated for the treatment of chronic hepatitis C in patients 3 years of age and older with compensated liver disease
use alone for the treatment of chronic hepatitis C in patients with compensated liver disease previously untreated with interferon alpha and who are at least 18 years of age and intolerant to ribavirin |
| Intron A | interferon alpha-2b | Schering | treatment of chronic hepatitis C in patients 18 years of age or older with compensated liver disease who have a history of blood or blood-product exposure and/or are HCV antibody positive |
| Rebetol | ribavirin | Schering | use in combination with Pegintron for treatment of chronic hepatitis C in patients with compensated liver disease who have not been previously treated with interferon alpha and are at least 18 years of age |
| Roferon | interferon alpha-2a | Roche | treatment of chronic hepatitis C in patients 18 years of age or older |
| Infergen | interferon aphacon-1 | Three Rivers Pharma | treatment of chronic hepatitis C in patients 18 years of age or older with compensated liver disease who have anti-HCV serum antibodies and/or HCV RNA |
-
-
